Algert Global’s Acorda Therapeutics ACOR Stock Holding History

Algert Global’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-249	Closed	-$466K	–	419
2018 Q4	$466K	Buy	+249	New	+$542K	0.13%	231

Other funds holding ACOR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Algert Global's ACOR Position: Q1 2019 in Review

Algert Global sold out of Acorda Therapeutics (ACOR) in Q1 2019, closing a stake of 249 shares — an estimated $466K sold.

Algert Global first reported a position in ACOR in Q4 2018 and held it in 1 quarter. The position peaked at $466K in Q4 2018. 184 funds tracked by Wall St. Rank hold ACOR as of Q1 2019.

Algert Global reported no remaining Acorda Therapeutics position as of Q1 2019 after selling out during the quarter.
Algert Global sold 249 Acorda Therapeutics shares in Q1 2019, an estimated $466K.
Algert Global first reported a position in Acorda Therapeutics in Q4 2018 and held it in 1 quarter.
Algert Global's Acorda Therapeutics position peaked at $466K in Q4 2018.
184 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2019.

Based on Algert Global's 13F filing for Q1 2019, filed 1 May 2019.